The Big Ones
Yuanfudao is the latest Chinese online education provider to raise a huge amount, reportedly securing $1bn in a series G2 round led by DST Global that valued it at $15.5bn post-money. Its earlier investors include Tencent, which co-led the company’s $1bn series G round in March at a $7.8bn valuation, and which was reported last month to be taking part in a $1.2bn round that media reports state had already closed in the run up to the series G2 funding.
Ant Group has secured regulatory approval for the Shanghai leg of a dual listing expected to raise some $35bn at a valuation that may top $250bn, having got clearance for the Hong Kong offering on Monday. Which would make it the biggest flotation in history. The financial services provider was valued at $150bn when it raised $14bn in its 2018 series C round, and Alibaba, which spun the company off, is set to buy about 20% of the shares being issued to come out with a 32% stake post-IPO.
The biggest fund this week is actually a crossover: UVC Partners, the Germany-based venture capital firm affiliated with Technical University of Munich (also known as TUM), unveiled its €150m ($178m) third fund on Tuesday backed by LPs including specialty chemicals company Lanxess. The co-founders of mobility services provider Flixbus also invested in the fund, as have a range of unnamed institutional investors, family offices, corporates and family businesses. UVC Partners maintains a close relationship with UnternehmerTUM, the university’s centre for innovation and business creation. The two entities actually share leadership in Helmut Schönenberger, who is the chief executive of UnternehmerTUM and a managing partner of UVC Partners.
Deal-wise, in crossover news, AavantiBio is the latest entrant to the genetic therapy space, launching on Thursday with $107m in series A funding, $15m of which came from genetic drug developer Sarepta Therapeutics. The spinout’s president and CEO had spent some eight years in an executive position at Sarepta and its core technology is based on University of Florida research. AavantiBio will concentrate on genetic therapeutics for rare diseases and its initial focus is on Friedreich’s Ataxia (FA), an inherited genetic disease that leads to central nervous system and cardiac dysfunction.
Google has reportedly invested $300m in Tokopedia, one of Southeast Asia’s largest e-commerce marketplaces, as part of a late-stage round already equipped with $500m from Temasek on its way to a targeted close around the $1bn mark. Tokopedia’s earlier investors include CyberAgent Capital, Alibaba and SoftBank vehicles Vision Fund, SoftBank Ventures Asia and SB Pan Asia Fund.
Shouqi Yueche is one of several companies that had seen funding drop off in the wake of China’s regulatory crackdown on its ride hailing sector, but it claims to have increased its registered users by more than 30% in the last year and has also pulled in ‘hundreds of millions of dollars’ in series C funding. The investors in the round have not been revealed but the company’s existing backers include Baidu and Nio Capital.
Arctic Wolf is one of the fastest rising operators in the cybersecurity scene, the cybersecurity concierge provider having raised $200m in a DTCP-backed series E round valuing it at $1.3bn. It had secured $60m in series D funding just seven months ago and its overall funding now stands at more than $350m. It is also moving its head office from California to Minnesota amidst plans to up headcount significantly.
Online education has thrived during the coronavirus pandemic but another Chinese company, online pharmacy operator Dingdang Kuaiyao, has also seen user numbers rise significantly. It has pulled in $150m through a series B-plus round that included existing backers Softbank China and Sinopharm-CICC Capital. Both had already taken part in the company’s $89m series B early last year.
VectivBio has closed a $110m crossover financing round that included Novo to advance its short bowel syndrome treatment through phase 3 clinical trials. The company was spun off from Therachon, a Novo-backed genetic disease therapy developer acquired for $810m in May last year. Novo had also been among the investors to provide the $35m VectivBio had when it launched in January this year.
Hyperscience has developed software that allows organisations to automate back-office tasks to increase efficiency, and has raised $80m in a series D round led by Tiger Global Management. The company’s earlier backers include QBE, TD Ameritrade and Penna and Company, and the series D round took its overall funding past the $190m mark.
Spain-based telecommunications firm Telefónica has launched a cybersecurity-focused investment vehicle called Telefónica Tech Ventures that expects to provide funding for 15 cybersecurity technology developers over the next three years, investing up to $7m per deal at series A to C stage. Follow-on funding will be available for the better performing recipients.
Big funding isn’t necessarily the fuel for success however, with short-form streaming service Quibi announcing yesterday it is set to shutter its platform, which launched just six months ago. It will have about $350m to return from the $1.75bn it raised from investors including Alibaba, Sony, 21st Century Fox, Walt Disney, WarnerMedia, Entertainment One and, reportedly, Google and Facebook. Quibi itself has blamed the coronavirus for much of its trouble getting subscribers, but the low adoption rate following free trials points to a lack of good programming and, perhaps deeper, to too many execs with TV experience and not enough with online expertise.
Quibi isn’t the only tech unicorn set to call it a day however. Chinese online car marketplace Renrenche has raised $760m from investors including Didi Chuxing and Tencent and was reportedly valued at $1.7bn after its most recent round in 2018, but Bloomberg has reported it is in talks to sell its major assets to 58.com for a token amount a little over $1,000. Renrenche’s branch of the startup space has been impacted heavily by the coronavirus, but it also competes in a crowded sector. These may be just the start of several parts of the startup space thinning out as revenues dip and money gets increasingly tight.
Back to some better news: although both the US and China have been hotbeds for tech IPOs in recent months, ride hailing has been visibly apart from that as the sector’s inhabitants look to offset the damage to their businesses done by the coronavirus. Dida Chuxing was recently reported to be mulling a Hong Kong IPO, and market leader Didi Chuxing is reportedly looking at the same destination for a 2021 offering. The purported IPO is expected to value Didi at up to $60bn and investors including SoftBank, Apple, Alibaba, China Life, Tencent, Booking Holdings, Ping An, eHi and Sina Weibo would be in line for exits.
Small molecule drug developer Aligos Therapeutics has raised $150m in an initial public offering that involved it pricing 10 million shares in the middle of their $14 to $16 range. Those shares are currently (that’s Friday afternoon UK time) at $15.12, but the offering nevertheless represents exits for Roche Finance and Novo, which were among the investors that had supplied more than $230m in venture funding for Aligos.
Advanced hearing aid provider Eargo on the other hand has celebrated a bumper IPO, floating above its range in an upsized offering to raise more than $141m, then seeing its shares open at double the IPO price on their first day of trading. You know who else must be celebrating? Nan Fung Life Sciences, which participated in Eargo’s last three rounds and which is now backing a company with a market cap over $1.2bn.
Compass Therapeutics is the latest drug developer to file for an initial public offering, though the $50m target it has set suggests its aim may be lower than most. The immuno-oncology therapy developer had secured $132m in a 2018 series A round featuring life sciences-focused real estate investment trusts Alexandria Real Estate Equities and Biomed Realty, but neither possess a stake in the company sized at 5% or greater.